Showing 1 - 10 of 10 for "Margrit Marti" with applied filters
M&A, Private equity
Banking and finance
Restructuring and insolvency
Capital markets : Debt, Capital markets : Equity, Capital markets : Structured finance and securitisation, Financial and corporate, Financial services regulatory, M&A, Restructuring and insolvency
Asset finance, Banking, Capital markets : Debt, Capital markets : Equity, Capital markets : Structured finance and securitisation, Financial and corporate, Financial services regulatory, Investment funds, M&A, Project development, Project finance, Restructuring and insolvency
23 December 2025 by
On December 21, 2025, Windward Bio Group AG, a Swiss-based private, clinical-stage biotechnology company committed to improving outcomes for people living with advanced immunological diseases, announced a licensing agreement between its affiliate, LE2025 Therapeutics AG, and Qyuns Therapeutics Co., Ltd. for the development and commercialization of WIN027 (also known as QX027N), a potential best-in-disease, long-acting bispecific antibody targeting TSLP and IL-13.
08 December 2025 by
On December 8, 2025, EQT announced the sale of an additional 10% stake in Galderma Group AG (SIX: GALD) by a consortium led by EQT, which includes Sunshine SwissCo GmbH (SSCO), Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte. Ltd. (all acting as sellers) to L’Oréal S.A.
24 November 2025 by
On November 20, 2025, Flexion Robotics, a Zurich-based technology company, announced that it had raised USD 50 million in Series A funding from DST Global Partners, NVentures (NVIDIA’s venture capital arm), redalpine, Prosus Ventures, and Moonfire.
06 August 2024 by
On August 5, 2024, L’Oréal and Galderma announced the acquisition of a 10% stake in Galderma Group AG from Sunshine SwissCo AG (a consortium led by EQT), Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte. Ltd.
19 October 2020 by
On October 15, 2020, VectivBio AG, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, announced that...